The ProShip Clinical Trial is evaluating the safety and effectiveness of an investigational drug in comparison to a placebo. The investigational drug, AQX-1125, being assessed in this trial represents a new class of compounds, activating the SHIP1 protein that may help modulate the inflammatory process. The study drug is administered orally once daily.  This is a randomized, multi-center, double-blind, parallel-group study, enrolling approximately 100 male subjects diagnosed with CP/CPPS to evaluate the effect of 12-week treatment with AQX-1125 (active drug) compared to placebo.

Name *